The Society of Thoracic Surgeons Intermacs 2020 Annual Report. [Review]

MedStar author(s):
Citation: Annals of Thoracic Surgery. 111(3):778-792, 2021 03.PMID: 33465365Institution: MedStar Heart & Vascular InstituteForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Heart Failure/su [Surgery] | *Heart-Assist Devices | *Registries | *Societies, Medical | *Surgeons | *Thoracic Surgery | Humans | United StatesYear: 2021Local holdings: Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007ISSN:
  • 0003-4975
Name of journal: The Annals of thoracic surgeryAbstract: The STS-Intermacs 2020 Annual Report reviews outcomes on 25,551 patients undergoing primary isolated continuous flow left ventricular assist device (LVAD) implantation between 2010-2019. In 2019, 3,198 primary LVADs were implanted, which is the highest annual volume in Registry history. Compared with the previous era (2010-2014), patients implanted in the most recent era (2015-2019) were more likely to be African American (26.8% vs. 22.9%, P<.0001) and more likely to be bridged to durable LVAD with temporary mechanical support devices (36.8% vs 26.0%, P<.0001). In 2019, 50% of patients were INTERMACS 1-2 prior to durable LVAD and 73% were implanted as destination therapy. Maglev technology has become the predominant design, accounting for 77% of devices in 2019. The 1- and 2-year survival in the most recent era has improved compared to 2010-2014 (82.3% and 73.1% vs. 80.5% and 69.1%, respectively; P<.0001). Major bleeding and infection continue to be the leading adverse events. Incident stroke has declined in the current era to 12.7% at one-year. STS-Intermacs research publications are highlighted herein and the new quality initiatives are introduced. Copyright (c) 2021. Published by Elsevier Inc.All authors: Badhwar V, Copeland H, Cornwell WK 3rd, Cowger JA, Fernandez FG, Habib RH, Jacobs JP, Kiernan MS, Kirklin JK, Koehl D, Molina EJ, Pagani FD, Shah P, Takeda KOriginally published: Annals of Thoracic Surgery. 2021 Jan 16Fiscal year: FY2021Digital Object Identifier: Date added to catalog: 2021-02-17
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 33465365 Available 33465365

Available online from MWHC library: 1995 - present, Available in print through MWHC library:1999-2007

The STS-Intermacs 2020 Annual Report reviews outcomes on 25,551 patients undergoing primary isolated continuous flow left ventricular assist device (LVAD) implantation between 2010-2019. In 2019, 3,198 primary LVADs were implanted, which is the highest annual volume in Registry history. Compared with the previous era (2010-2014), patients implanted in the most recent era (2015-2019) were more likely to be African American (26.8% vs. 22.9%, P<.0001) and more likely to be bridged to durable LVAD with temporary mechanical support devices (36.8% vs 26.0%, P<.0001). In 2019, 50% of patients were INTERMACS 1-2 prior to durable LVAD and 73% were implanted as destination therapy. Maglev technology has become the predominant design, accounting for 77% of devices in 2019. The 1- and 2-year survival in the most recent era has improved compared to 2010-2014 (82.3% and 73.1% vs. 80.5% and 69.1%, respectively; P<.0001). Major bleeding and infection continue to be the leading adverse events. Incident stroke has declined in the current era to 12.7% at one-year. STS-Intermacs research publications are highlighted herein and the new quality initiatives are introduced. Copyright (c) 2021. Published by Elsevier Inc.

English

Powered by Koha